Paul Tudor Jones Oncorus, Inc. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$13.3 - $17.3 $748,936 - $974,180
-56,311 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$11.89 - $35.55 $669,537 - $2 Million
56,311 New
56,311 $784,000

About Oncorus, Inc.

ONCR Quotes by TradingView
  • Ticker ONCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,973,100
  • Description
  • Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...
More about ONCR
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email